tiprankstipranks
Legend Biotech Corporation (LEGN)
NASDAQ:LEGN
US Market
LEGN
Legend Biotech
RESEARCH TOOLSreports
Want to see LEGN full AI Analyst Report?

Legend Biotech (LEGN) Stock Forecast & Price Target

733 Followers
See the Price Targets and Ratings of:

LEGN Analyst Ratings

Moderate Buy
10Ratings
Moderate Buy
6 Buy
4 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Legend
Biotech
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

LEGN Stock 12 Month Forecast

Average Price Target

$48.07
▲(116.34% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Legend Biotech in the last 3 months. The average price target is $48.07 with a high forecast of $78.00 and a low forecast of $24.00. The average price target represents a 116.34% change from the last price of $22.22.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","79":"$79","31.75":"$31.8","47.5":"$47.5","63.25":"$63.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$78.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48.07,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$48.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,31.75,47.5,63.25,79],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.55,23.123076923076923,27.696153846153848,32.269230769230774,36.8423076923077,41.415384615384625,45.98846153846154,50.56153846153846,55.13461538461539,59.70769230769231,64.28076923076924,68.85384615384616,73.42692307692309,{"y":78,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.55,20.82076923076923,23.091538461538462,25.362307692307695,27.633076923076924,29.903846153846153,32.174615384615386,34.44538461538462,36.716153846153844,38.98692307692308,41.25769230769231,43.52846153846154,45.799230769230775,{"y":48.07,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.55,18.96923076923077,19.388461538461538,19.807692307692307,20.22692307692308,20.646153846153847,21.065384615384616,21.484615384615385,21.903846153846153,22.323076923076922,22.74230769230769,23.161538461538463,23.58076923076923,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":38.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.22,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.66,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.4,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.84,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.74,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.15,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.44,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.05,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.59,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.51,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.89,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.55,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$78.00Average Price Target$48.07Lowest Price Target$24.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on LEGN
Ashwani Verma
UBS
UBS
$28
Hold
26.01%
Upside
Assigned
08/13/26
Analysts Conflicted on These Healthcare Names: Legend Biotech (NASDAQ: LEGN), GoodRx Holdings (NASDAQ: GDRX) and CytomX Therapeutics (NASDAQ: CTMX)
TD Cowen Analyst forecast on LEGN
Yaron Werber
TD Cowen
TD Cowen
$29→$24
Hold
8.01%
Upside
Assigned
08/12/26
TD Cowen Sticks to Its Hold Rating for Legend Biotech (LEGN)
Morgan Stanley Analyst forecast on LEGN
Terence Flynn
Morgan Stanley
Morgan Stanley
$49→$48
Buy
116.02%
Upside
Reiterated
08/12/26
Legend Biotech (LEGN) Receives a Buy from Morgan Stanley
Goldman Sachs Analyst forecast on LEGN
Ziyi Chen
Goldman Sachs
Goldman Sachs
$40.5→$40.7
Buy
83.17%
Upside
Reiterated
08/12/26
Goldman Sachs Reaffirms Their Buy Rating on Legend Biotech (LEGN)
Oppenheimer Analyst forecast on LEGN
Kostas Biliouris
Oppenheimer
Oppenheimer
$75→$40
Hold
80.02%
Upside
Downgraded
08/12/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intuitive Surgical (NASDAQ: ISRG), Legend Biotech (NASDAQ: LEGN) and Mineralys Therapeutics, Inc. (NASDAQ: MLYS)
Barclays Analyst forecast on LEGN
Etzer Darout
Barclays
Barclays
$80→$78
Buy
251.04%
Upside
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA), AbbVie (NYSE: ABBV) and Legend Biotech (NASDAQ: LEGN)
RBC Capital Analyst forecast on LEGN
Leonid Timashev
RBC Capital
RBC Capital
$59→$58
Buy
161.03%
Upside
Assigned
08/11/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Brookdale Senior Living (NYSE: BKD) and Legend Biotech (NASDAQ: LEGN)
H.C. Wainwright Analyst forecast on LEGN
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$65
Buy
192.53%
Upside
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Immunic (NASDAQ: IMUX), Legend Biotech (NASDAQ: LEGN) and Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT)
J.P. Morgan Analyst forecast on LEGN
Jessica Fye
J.P. Morgan
J.P. Morgan
$35
Hold
57.52%
Upside
Initiated
07/13/26
Legend Biotech resumed with a Neutral at JPMorganLegend Biotech resumed with a Neutral at JPMorgan
Piper Sandler Analyst forecast on LEGN
Edward Tenthoff
Piper Sandler
Piper Sandler
$64
Buy
188.03%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Ascendis Pharma (NASDAQ: ASND) and Lyell Immunopharma (NASDAQ: LYEL)
Truist Financial Analyst forecast on LEGN
Asthika Goonewardene
Truist Financial
Truist Financial
$70
Buy
215.03%
Upside
Reiterated
03/13/26
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN) and Medtronic (NYSE: MDT)
Deutsche Bank Analyst forecast on LEGN
James Shin
Deutsche Bank
Deutsche Bank
$60
Buy
170.03%
Upside
Reiterated
03/09/26
Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Lantheus (LNTH)
Rothschild & Co Redburn Analyst forecast on LEGN
Qize Ding
Rothschild & Co Redburn
Rothschild & Co Redburn
$83→$24
Hold
8.01%
Upside
Downgraded
02/12/26
Legend Biotech downgraded to Neutral from Buy at Rothschild & Co RedburnLegend Biotech downgraded to Neutral from Buy at Rothschild & Co Redburn
Cantor Fitzgerald Analyst forecast on LEGN
Eric Schmidt FCA
Cantor Fitzgerald
Cantor Fitzgerald
$75→$74
Buy
233.03%
Upside
Reiterated
12/17/25
Legend Biotech price target lowered to $74 from $75 at Cantor FitzgeraldLegend Biotech price target lowered to $74 from $75 at Cantor Fitzgerald
William Blair Analyst forecast on LEGN
Sami Corwin
William Blair
William Blair
―
Hold
―
Reiterated
11/12/25
Legend Biotech's Strategic Growth and Risks: Analyst Assigns Hold Rating
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on LEGN
Ashwani Verma
UBS
UBS
$28
Hold
26.01%
Upside
Assigned
08/13/26
Analysts Conflicted on These Healthcare Names: Legend Biotech (NASDAQ: LEGN), GoodRx Holdings (NASDAQ: GDRX) and CytomX Therapeutics (NASDAQ: CTMX)
TD Cowen Analyst forecast on LEGN
Yaron Werber
TD Cowen
TD Cowen
$29→$24
Hold
8.01%
Upside
Assigned
08/12/26
TD Cowen Sticks to Its Hold Rating for Legend Biotech (LEGN)
Morgan Stanley Analyst forecast on LEGN
Terence Flynn
Morgan Stanley
Morgan Stanley
$49→$48
Buy
116.02%
Upside
Reiterated
08/12/26
Legend Biotech (LEGN) Receives a Buy from Morgan Stanley
Goldman Sachs Analyst forecast on LEGN
Ziyi Chen
Goldman Sachs
Goldman Sachs
$40.5→$40.7
Buy
83.17%
Upside
Reiterated
08/12/26
Goldman Sachs Reaffirms Their Buy Rating on Legend Biotech (LEGN)
Oppenheimer Analyst forecast on LEGN
Kostas Biliouris
Oppenheimer
Oppenheimer
$75→$40
Hold
80.02%
Upside
Downgraded
08/12/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intuitive Surgical (NASDAQ: ISRG), Legend Biotech (NASDAQ: LEGN) and Mineralys Therapeutics, Inc. (NASDAQ: MLYS)
Barclays Analyst forecast on LEGN
Etzer Darout
Barclays
Barclays
$80→$78
Buy
251.04%
Upside
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA), AbbVie (NYSE: ABBV) and Legend Biotech (NASDAQ: LEGN)
RBC Capital Analyst forecast on LEGN
Leonid Timashev
RBC Capital
RBC Capital
$59→$58
Buy
161.03%
Upside
Assigned
08/11/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Brookdale Senior Living (NYSE: BKD) and Legend Biotech (NASDAQ: LEGN)
H.C. Wainwright Analyst forecast on LEGN
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$65
Buy
192.53%
Upside
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Immunic (NASDAQ: IMUX), Legend Biotech (NASDAQ: LEGN) and Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT)
J.P. Morgan Analyst forecast on LEGN
Jessica Fye
J.P. Morgan
J.P. Morgan
$35
Hold
57.52%
Upside
Initiated
07/13/26
Legend Biotech resumed with a Neutral at JPMorganLegend Biotech resumed with a Neutral at JPMorgan
Piper Sandler Analyst forecast on LEGN
Edward Tenthoff
Piper Sandler
Piper Sandler
$64
Buy
188.03%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Ascendis Pharma (NASDAQ: ASND) and Lyell Immunopharma (NASDAQ: LYEL)
Truist Financial Analyst forecast on LEGN
Asthika Goonewardene
Truist Financial
Truist Financial
$70
Buy
215.03%
Upside
Reiterated
03/13/26
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN) and Medtronic (NYSE: MDT)
Deutsche Bank Analyst forecast on LEGN
James Shin
Deutsche Bank
Deutsche Bank
$60
Buy
170.03%
Upside
Reiterated
03/09/26
Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Lantheus (LNTH)
Rothschild & Co Redburn Analyst forecast on LEGN
Qize Ding
Rothschild & Co Redburn
Rothschild & Co Redburn
$83→$24
Hold
8.01%
Upside
Downgraded
02/12/26
Legend Biotech downgraded to Neutral from Buy at Rothschild & Co RedburnLegend Biotech downgraded to Neutral from Buy at Rothschild & Co Redburn
Cantor Fitzgerald Analyst forecast on LEGN
Eric Schmidt FCA
Cantor Fitzgerald
Cantor Fitzgerald
$75→$74
Buy
233.03%
Upside
Reiterated
12/17/25
Legend Biotech price target lowered to $74 from $75 at Cantor FitzgeraldLegend Biotech price target lowered to $74 from $75 at Cantor Fitzgerald
William Blair Analyst forecast on LEGN
Sami Corwin
William Blair
William Blair
―
Hold
―
Reiterated
11/12/25
Legend Biotech's Strategic Growth and Risks: Analyst Assigns Hold Rating
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Legend Biotech

3 Months
Edward TenthoffPiper Sandler
Success Rate
7/17 ratings generated profit
41%
Average Return
+3.23%
Copying Edward Tenthoff's trades and holding each position for 3 Months would result in 41.18% of your transactions generating a profit, with an average return of +3.23% per trade.
1 Year
Edward TenthoffPiper Sandler
Success Rate
5/17 ratings generated profit
29%
Average Return
-18.04%
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 29.41% of your transactions generating a profit, with an average return of -18.04% per trade.
2 Years
Mitchell KapoorH.C. Wainwright
Success Rate
4/38 ratings generated profit
11%
Average Return
-37.58%
Copying Mitchell Kapoor's trades and holding each position for 2 Years would result in 10.53% of your transactions generating a profit, with an average return of -37.58% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LEGN Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
20
27
24
22
18
Buy
0
0
2
2
2
Hold
2
2
1
3
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
22
29
27
27
25
In the current month, LEGN has received 20 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. LEGN average Analyst price target in the past 3 months is 48.07.
Each month's total comprises the sum of three months' worth of ratings.

LEGN Financial Forecast

LEGN Earnings Forecast

Next quarter’s earnings estimate for LEGN is $0.01 with a range of -$0.05 to $0.17. The previous quarter’s EPS was $0.09. LEGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year LEGN has Performed in-line its overall industry.
Next quarter’s earnings estimate for LEGN is $0.01 with a range of -$0.05 to $0.17. The previous quarter’s EPS was $0.09. LEGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year LEGN has Performed in-line its overall industry.

LEGN Sales Forecast

Next quarter’s sales forecast for LEGN is $361.43M with a range of $340.95M to $378.70M. The previous quarter’s sales results were $388.14M. LEGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year LEGN has Performed in-line its overall industry.
Next quarter’s sales forecast for LEGN is $361.43M with a range of $340.95M to $378.70M. The previous quarter’s sales results were $388.14M. LEGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year LEGN has Performed in-line its overall industry.

LEGN Stock Forecast FAQ

What is LEGN’s average 12-month price target, according to analysts?
Based on analyst ratings, Legend Biotech Corporation’s 12-month average price target is 48.07.
    What is LEGN’s upside potential, based on the analysts’ average price target?
    Legend Biotech Corporation has 116.34% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is LEGN a Buy, Sell or Hold?
          Legend Biotech Corporation has a consensus rating of Moderate Buy which is based on 6 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Legend Biotech Corporation’s price target?
            The average price target for Legend Biotech Corporation is 48.07. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $78.00 ,the lowest forecast is $24.00. The average price target represents 116.34% Increase from the current price of $22.22.
              What do analysts say about Legend Biotech Corporation?
              Legend Biotech Corporation’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of LEGN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.